Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours 1

1040 - High anus preservation and low toxicity rates in a phase I trial of neoadjuvant bowel-sparing IMRT/bevacizumab/FOLFOX and TME for locally advanced rectal cancer


20 Dec 2015


Gastrointestinal tumours 1


Jason Chia-Hsien Cheng


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


J.C. Cheng1, J. Liang2, C. Tsai1, J. Hung2, J. Huang2, Y. Lin3, C. Wang1

Author affiliations

  • 1 Department Of Radiation Oncology, National Taiwan University Hospital, 10002 - Taipei/TW
  • 2 Department Of Surgery, National Taiwan University Hospital, 10002 - Taipei/TW
  • 3 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei/TW

Abstract 1040


A significant proportion of patients with locally advanced rectal cancer encountered ≧ grade 3 toxicity and postoperative complications in trials adding bevacizumab (BV) to preoperative chemotherapy and conventional radiotherapy. The aims of this phase I trial were to determine the maximum tolerated dose (MTD) and pathological complete response (pCR) rate of neoadjuvant dose-escalated intensity modulated radiation therapy (IMRT), combined with BV and 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) followed by total mesorectal excision (TME).


Patients with clinical T3-4 or N+ and M0 rectal adenocarcinoma were treated in 3 escalating dose levels (45 Gy/50 Gy/55 Gy in 25 fractions) of prone-positioned IMRT on belly board to spare small bowels. Patients received BV (5 mg/kg) and FOLFOX concurrently with IMRT in week 1, 3, and 5 for 3 cycles. TME was carried out 6-10 weeks following completion of IMRT.


Fifteen patients (5 at each IMRT dose level) were enrolled and completed IMRT, BV/FOLFOX, and TME. Twelve patients had rectal tumor within 5 cm from anal verge. No patient had grade 4 toxicity, and 5 patients had grade 3 acute toxicity, including 2 (13%) with afebrile neutropenia, 2 (13%) with anal skin reaction, and 1 (7%) with diarrhea. The MTD was not reached. Fourteen of 15 patients had anus preservation surgery, and 13 (87%) maintained functional anus. The median hospital stay of TME was 9 days (8-24 days). One (7%) patient had grade 3 postoperative bowel obstruction requiring reoperation. Of 15 patients, 5 (33%) had pCR, and 13 (87%) had downstaging effect. Rectal tumor volume <100 ml at diagnosis was significantly associated with pCR (5/12 vs. 0/3, p = 0.016). Post-/pre-IMRT serum VEGFa ratio <1 was significantly associated with nodal downstage (8/8 vs. 4/6, p = 0.046). With a median follow-up of 25.1 months, 1 patient developed liver metastasis, and no patient had local recurrence or died. The 3-year disease-free survival was 83%.


High pCR and anus preservation rates, as well as low toxicity rates, were achieved by neoadjuvant bowel-sparing IMRT, BV, FOLFOX, and TME. Rectal tumor volume <100 ml was associated with pCR.

Clinical trial identification



J.C.-H. Cheng: Bevacizumab in this trial was sponsored by Roche, and oxaliplatin was sponsored by TTY Biopharm. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings